The Report “PharmaPoint: Prophylactic Hepatitis B Virus
Vaccines – US Drug Forecast and Market Analysis to 2022″ by GlobalData is now
available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com
with “PharmaPoint: Prophylactic Hepatitis B Virus Vaccines – US Drug Forecast
and Market Analysis to 2022″ in subject line and your contact details to
purchase this report or get your questions answered.
Hepatitis B, which is caused by the hepatitis
B virus (HBV), is characterized by acute or chronic inflammation of the
liver. Researchers and healthcare experts have estimated that roughly two
billion people are infected with HBV worldwide, with roughly 600,000 people
dying each year from HBV-related liver diseases. While the arrival of
recombinant HBsAg vaccines has greatly reduced disease burden over the past two
decades, questions surrounding vaccine uptake and effectiveness in adults,
particularly in niche patient populations, still remain. It expects that the
growing popularity of pediatric combination vaccines, along with the arrival of
vaccines that achieve higher seroconversion rates in high-risk adults, will
serve to stimulate growth in the marketplace over the forecast period.
Country-specific immunization recommendations and policy implementation will be
an essential metric for determining future vaccine uptake in the 7MM (US,
France, Germany, Italy, Spain, UK, and Japan) and Canada.
The drivers and barriers that projects to most heavily
influence growth of the US HBV vaccine market during the forecast period. In
the pediatric segment of the marketplace, where annual coverage rates
consistently reach 90%, this growth will be driven primarily by the increased
use of combination vaccines for routine immunization, as these vaccines are
looked upon favorably by both parents and physicians due to their ability to
protect infants against multiple diseases with a single series of shots.
Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=164946
.
Scope
·
Overview
of Hepatitis B disease including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive
landscape.
·
Detailed
information on the key drugs in the US including product description, safety
and efficacy profiles as well as a SWOT analysis.
·
Sales
forecast for the top drugs in the US from 2012-2022.
·
Analysis
of the impact of key events as well the drivers and restraints affecting the US
Hepatitis B disease market.
Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-prophylactic-hepatitis-b-virus-vaccines-us-drug-forecast-and-market-analysis-to-2022-market-report.html
. Read more on “PharmaPoint:
Prophylactic Hepatitis B Virus Vaccines – US Drug Forecast and Market Analysis
to 2022” report below.
Reasons to buy
·
Understand
and capitalize by identifying products that are most likely to ensure a robust
return
·
Stay
ahead of the competition by understanding the changing competitive landscape
for Hepatitis B disease
·
Effectively
plan your M&A and partnership strategies by identifying drugs with the most
promising sales potential
·
Make
more informed business decisions from insightful and in-depth analysis of drug
performance
·
Obtain
sales forecast for drugs from 2012-2022 in the US
Buy a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=164946
.
For further information on “PharmaPoint: Prophylactic
Hepatitis B Virus Vaccines – US Drug Forecast and Market Analysis to 2022”
report OR for any other business research / market intelligence need on the ‘Hepatitis-Drugs’
market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/hepatitis-drugs . ), contact sales@rnrmarketresearch.com /
Call +1 888 391 5441.
